Analyst Price Targets — VTRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 10:05 am | Ashwani Verma | UBS | $18.00 | $14.58 | TheFly | Viatris upgraded to Buy from Neutral at UBS |
| January 28, 2026 11:49 am | — | Piper Sandler | $12.00 | $13.12 | TheFly | Viatris price target raised to $12 from $9 at Piper Sandler |
| January 16, 2026 12:14 pm | — | Argus Research | $15.00 | $12.84 | TheFly | Argus upgrades Viatris to Buy on expected buybacks, debt reduction |
| January 7, 2026 12:22 pm | Les Sulewski | Truist Financial | $16.00 | $12.40 | TheFly | Viatris price target raised to $16 from $15 at Truist |
| October 15, 2025 10:07 am | — | Truist Financial | $15.00 | $9.93 | TheFly | Viatris initiated with a Buy at Truist |
| July 19, 2024 8:05 am | Glen Santangelo | Jefferies | $15.00 | $11.77 | TheFly | Viatris reinstated with a Buy at Jefferies |
| March 28, 2024 6:40 am | David Amsellem | Piper Sandler | $13.00 | $11.83 | StreetInsider | Viatris (VTRS) PT Raised to $13 at Piper Sandler on latest Idorsia deals |
| June 26, 2023 9:08 am | David Amsellem | Piper Sandler | $10.00 | $9.84 | Benzinga | Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts |
| February 1, 2023 8:09 am | — | Barclays | $15.00 | $12.16 | Benzinga | Barclays Maintains Overweight on Viatris, Lowers Price Target to $15 |
| November 9, 2022 4:08 pm | Ashwani Verma | UBS | $12.00 | $10.83 | StreetInsider | UBS Upgrades Viatris (VTRS) to Neutral |
Latest News for VTRS
PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m.
PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI), for the…
Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxicam and Low-Dose Estrogen Weekly Patch in the U.S., and Pitolisant and Effexor® for GAD in Japan Unlocking Long-Term Value Through Potential Blockbusters Selatogrel and Cenerimod Strong Cash Flow Generation Enabling…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.